Alterations in the Levels of Circulating and Endothelial Progenitor Cells Levels in Young Adults with Type 1 Diabetes: A 2-Year Follow-Up from the Observational METRO Study

References

• Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA. 2015;313(1):37–44. doi:10.1001/jama.2014.16425
   PubMed Web of Science ®Google Scholar
• Huo L, Shaw JE, Wong E, Harding JL, Peeters A, Magliano DJ. Burden of diabetes in Australia: life expectancy and disability-free life expectancy in adults with diabetes. Diabetologia. 2016;59(7):1437–1445. doi:10.1007/s00125-016-3948-x
   PubMedGoogle Scholar
• Maahs DM, Daniels SR, de Ferranti SD, et al. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2014;130(17):1532–1558. doi:10.1161/CIR.0000000000000094
   PubMedGoogle Scholar
• Gorst C, Kwok CS, Aslam S, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354–2369. doi:10.2337/dc15-1188
   PubMed Web of Science ®Google Scholar
• Saad MI, Abdelkhalek TM, Saleh MM, et al. Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells. Endocrine. 2015;50(3):537–567.
   PubMed Web of Science ®Google Scholar
• Lombardo MF, Iacopino P, Cuzzola M, et al. Type 2 diabetesmellitus impairs the maturation of endothelial progenitor cells and increases the number of circulating endothelial cells in peripheral blood. Cytometry A. 2012;81:856–864. doi:10.1002/cyto.a.22109
   PubMedGoogle Scholar
• Loomans CJ, de Koning EJ, Staal FJ, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes. 2004;53:95–199. doi:10.2337/diabetes.53.1.195
   Google Scholar
• Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004;95(4):343–353. doi:10.1161/01.RES.0000137877.89448.78
   PubMed Web of Science ®Google Scholar
• Urbich C, Aicher A, Heeschen C, et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol. 2005;39(5):733–742. doi:10.1016/j.yjmcc.2005.07.003
   PubMed Web of Science ®Google Scholar
• Rigato M, Avogaro A, Fadini GP. Levels of circulating progenitor cells, cardiovascular outcomes and death: a meta-analysis of prospective observational Studies. Circ Res. 2016;118(12):1930–1939. doi:10.1161/CIRCRESAHA.116.308366
   PubMedGoogle Scholar
• Maiorino MI, Della Volpe E, Olita L, Bellastella G, Giugliano D, Esposito K. Glucose variability inversely associates with endothelial progenitor cells in type 1 diabetes. Endocrine. 2015;48(1):342–345. doi:10.1007/s12020-014-0277-z
   PubMedGoogle Scholar
• Rigato M, Fadini GP. Circulating stem/progenitor cells as prognostic biomarkers in macro- and microvascular disease: a narrative review of prospective observational studies. Curr Med Chem. 2018;25(35):4507–4517. doi:10.2174/0929867324666170920154020
   PubMedGoogle Scholar
• Hörtenhuber T, Rami-Mehar B, Satler M, et al. Endothelial progenitor cells are related to glycemic control in children with type 1 diabetes over time. Diabetes Care. 2013;36(6):1647–1653. doi:10.2337/dc12-1206
   PubMedGoogle Scholar
• Ahmed FW, Rider R, Glanville M, Narayanan K, Razvi S, Weaver JU. Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study. Cardiovasc Diabetol. 2016;15(1):116. doi:10.1186/s12933-016-0413-6
   PubMed Web of Science ®Google Scholar
• Maiorino MI, Casciano O, Della Volpe E, Bellastella G, Giugliano D, Esposito K. Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study. Endocrine. 2016;52(2):244–252. doi:10.1007/s12020-015-0686-7
   PubMedGoogle Scholar
• Maiorino MI, Bellastella G, Casciano O, et al. The effects of subcutaneous insulin infusion versus multiple insulin injections on glucose variability in young adults with type 1 diabetes: the 2-year follow-up of the observational METRO Study. Diabetes Technol Ther. 2018;20(2):117–126. doi:10.1089/dia.2017.0334
   PubMedGoogle Scholar
• Fadini GP, Mehta A, Dhindsa DS, et al. Circulating stem cells and cardiovascular outcomes: from basic science to the clinic. Eur Heart J. 2019. doi:10.1093/eurheartj/ehz923
   Google Scholar
• Fadini GP. A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications. Diabetologia. 2014;57(1):4–15. doi:10.1007/s00125-013-3087-6
   PubMedGoogle Scholar
• Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353(10):999–1007. doi:10.1056/NEJMoa043814
   PubMed Web of Science ®Google Scholar
• Cavalot F. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. Diabetes Obes Metab. 2013;15(2):3–8. doi:10.1111/dom.12140
   PubMedGoogle Scholar
• Lachin JM, Bebu I, Bergenstal RM, et al. Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the Diabetes Control and Complications Trial. Diabetes Care. 2017;40(6):777–783. doi:10.2337/dc16-2426
   PubMedGoogle Scholar
• Kilpatrick ES, Rigby AS, Atkin SL, et al. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care. 2009;32(10):1901–1903. doi:10.2337/dc09-0109
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Bode BW, Garg S, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005;28(3):533–538. doi:10.2337/diacare.28.3.533
   PubMed Web of Science ®Google Scholar
• Bruttomesso D, Crazzolara D, Maran A, et al. In type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet Med. 2008;25(3):326–332. doi:10.1111/dme.2008.25.issue-3
   PubMed Web of Science ®Google Scholar
• Maiorino MI, Bellastella G, Petrizzo M, et al. Treatment satisfaction and glycemic control in young type 1 diabetic patients in transition from pediatric health care: CSII versus MDI. Endocrine. 2014;46(2):256–262. doi:10.1007/s12020-013-0060-6
   PubMedGoogle Scholar
• Steineck I, Cederholm J, Eliasson B, et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ. 2015;350:h3234. doi:10.1136/bmj.h3234
   PubMed Web of Science ®Google Scholar
• Hernandez SL, Gong JH, Chen L, et al. Characterization of circulating and endothelial progenitor cells in patients with extreme-duration type 1 diabetes. Diabetes Care. 2014;37(8):2193–2201. doi:10.2337/dc13-2547
   PubMedGoogle Scholar
• Rigato M, Bittante C, Albiero M, Avogaro A, Fadini GP. Circulating progenitor cell count predicts microvascular outcomes in type 2 diabetic patients. J Clin Endocrinol Metab. 2015;100(7):2666–2672. doi:10.1210/jc.2015-1687
   PubMedGoogle Scholar